A study showed a 600% increase in GLP-1 receptor agonist dispensing among adolescents and young adults from 2020 to 2023, particularly among girls and young women. The surge in interest is linked to the FDA approval of semaglutide for weight loss in adults and adolescents. The findings highlight the need for education on sex-specific safety risks associated with GLP-1 receptor agonists, as well as the demand for these medications in younger populations. Primary care physicians may require training on this new class of medications due to the shortage of specialists. The study also noted limitations, such as a lack of data on prescription indications.
Source link
GLP-1 dispensing among adolescents, young adults rose from 2020 to 2023
